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Edited by Veli-Pekka LehtoAbstract The HBx protein of hepatitis B virus is involved in
deregulation of cell cycle and development of hepatocellular
carcinoma. Since c-Myc also plays an important role in cell
proliferation and tumor development, we studied its regulation
by HBx in a human hepatoma cell line. Co-expression of HBx
and c-Myc resulted in increased stability of intracellular
c-Myc. HBx blocked the ubiquitination of Myc through a direct
interaction with the F box region of Skp2 and destabiliza-
tion of the SCFSkp2 complex. We suggest that sustained
presence of c-Myc combined with mitogenic activity inherent
to HBx may be associated with cell cycle deregulation and
transformation.
 2005 Federation of European Biochemical Societies. Published
by Elsevier B.V. All rights reserved.
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Ubiquitination1. Introduction
Oncogenic viruses have evolved diﬀerent strategies of sub-
verting host cell functions to facilitate self replication and
productive infection. The gene products of such viruses gen-
erally target common transcription factors (such as c-myc
and NF-jB) or cell-signaling pathways to protract cell cycle
progression and inhibit apoptosis [1,2]. Viral proteins can
also inﬂuence cellular functions by regulating the levels of
target proteins via the ubiquitin (Ub)-dependent proteolysis
that requires sequential action of Ub-activating enzyme
(E1), Ub-conjugating enzyme (E2) and Ub ligase (E3) in
the Skp1-Cullin1-F box protein (SCF) complex [3,4]. The pre-
dilection for targeting proteasomes is a recurrent theme ob-
served in the cellular biology of several oncogenic viruses.
Viruses not only regulate host-encoded E3 ligases but also en-
code their own Ub ligases to disrupt cellular homeostasis of
vital transcription factors [5–9]. The X protein (HBx) of hep-
atitis B virus (HBV), which plays a major role in hepatocel-
lular carcinoma (HCC) [10], has also been shown toAbbreviations: b-TrCP, b-transducin repeat-containing protein; DN,
dominant negative; HBV, hepatitis B virus; HBx, X protein of HBV;
IgH, Immunoglobulin heavy chain; HA, haemagglutinin; HCC, hep-
atocellular carcinoma; LRR, leucine-rich repeat; SCF, Skp1-Cullin1-F
box protein; SDS–PAGE, SDS–polyacrylamide gel electrophoresis;
Ub, ubiquitin
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some [11,12]. This could downregulate the proteolytic activi-
ties of 20S and 26S proteasomes which in turn may regulate
the transactivation function of HBx and a subdued viral anti-
gen presentation by the infected cells [11]. It may also facili-
tate an active viral replication and production of infective
viruses through evasion of the host immune response and
establishment of persistent viral infection [13]. Further, HBx
can increase the rate of c-myc transcription [14] and facilitate
its proliferative action leading to HCC in transgenic mice
[15,16]. However, the molecular mechanism of oncogenic
cooperation between HBx and c-Myc is not clear. In the pres-
ent study, we investigated the regulation of c-Myc by the
SCFSkp2 complex in the presence of HBx.2. Materials and methods
2.1. Cell culture and transfection
Human Hepatoma Huh7 cells were maintained in Dulbecco’s mod-
iﬁed eagle medium (DMEM) with 10% fetal bovine serum (FBS) (Hy-
clone, USA) and seeded at a density of 0.7 million per 60 mm dish.
Transfections were carried out using Lipofectin (Invitrogen, USA) as
per manufacturer’s protocol.2.2. Chemicals and antibodies
Antibodies for Myc, Skp1, Skp2, Cul1, p21Waf1, Ub and b-Catenin
were purchased from Santa Cruz Biotechnologies (California, USA).
Antibodies for Myc- (Ab-1) and Flag tags were procured from Calbio-
chem (California, USA) and Sigma, respectively. Monoclonal anti-
body against HBx has been described earlier [17]. Protein-A
sepharose and protease inhibitor cocktail were procured from Amer-
sham Biotech, UK. The proteasome inhibitor MG132 was purchased
from Calbiochem.2.3. Expression vectors
Construction of expression vectors for HBx (X0) [17] and c-Myc [18]
have been described previously. Other expression vectors used were:
full length Skp2 with N-terminal Myc tag (pcDNA3 MT-Skp2) [19];
DF-Skp2 with FLAG tag (pcDNA-FLAG/DF Skp2) [20]; b-transducin
repeat-containing protein (b-TrCP) with Myc tag [21]; Ub with hae-
magglutinin (HA) tag (Ub, MT123) [22] and HA-tagged p21Waf1
[23]. The carboxy-terminal truncated mutant of Skp2 (DC Skp2) was
generated from the pcDNA3 MT-Skp2 construct by cloning a 700
bp Hind III-PstI fragment in the pSGI vector [18].2.4. Pulse chase analysis
Transfected cells (after 44 h) were pulse labeled with 213 pmol
(0.25 mCi) of [35S]-methionine and cysteine mix (Amersham Biotech)
for 15 min and chased with cold medium for diﬀerent time periods.
Cell-lysateswere immunoprecipitated, resolvedbySDS–polyacrylamide
gel electrophoresis (SDS–PAGE) and visualized by autoradiography.blished by Elsevier B.V. All rights reserved.
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These methods were performed as described previously [18].Fig. 2. Stability of HBx in the presence of Skp2. Huh7 cells were
transfected with (1 lg each) either X0 alone (lanes 1–4) or X0 with DF
Skp2 (lanes 5–8), pulse labeled with [35S] methionine and cysteine mix
followed by cold chase for diﬀerent time periods. The cell lysates were
immunoprecipitated using anti-HBx antibody and resolved by 12%
SDS–PAGE. In lower panel, samples 5–8 were directly immunoblotted
with anti-FLAG antibody to show the expression of DF Skp2.3. Results
3.1. HBx interacts with Skp2
Since intracellular c-Myc levels are regulated by at least two
F box proteins, viz., Skp2 and Fbw7 [19–22], we studied the
interaction of HBx with the F box protein Skp2. Immunopre-
cipitation results suggested that HBx interacted with Skp2 in a
cellular environment (Fig. 1A, lane 2). The interaction was
through the amino-terminal F box region of Skp2 since HBx
bound to the carboxy-terminal deletion mutant DC Skp2 (B,
lane 2) but failed to interact with DF Skp2 (C, lane 3). The
HBx-Skp2 interaction was speciﬁc because another F box pro-
tein b-TrCP did not recognize HBx (D, lane 3) although it
bound speciﬁcally to b-Catenin (E, lane 2).
3.2. Skp2 does not mediate the proteasomal degradation of HBx
Since HBx is reported to undergo proteasomal degradation
[11,23], we studied the involvement of Skp2 in this process.
The stability of HBx was monitored in the presence DF Skp2
– the dominant negative (DN) mutant of Skp2. As shown in
Fig. 2, no change in the biochemical stability HBx was observed
in the presence of DF Skp2 (compare lanes 5–8 with 1–4) and as
reported earlier [11] it exhibited a half-life of 30 min.
3.3. HBx disrupts the interaction between Skp1 and Skp2 and
destabilizes SCF complex
To unravel the consequence of interaction between HBx
and Skp2, the state of SCF complex were monitored using
two diﬀerent substrates of Skp2 – c-Myc and p21Waf1 –
the key regulators of cell cycle. Immunoprecipitation studies
suggested that the interactions between c-Myc and Skp2,Fig. 1. Interaction of HBx with Skp2. Huh7 cells were transfected with 1–2 l
along with DC Skp2 (B), DF Skp2 (C) and b-TrCP (D) or b-TrCP alone (E
indicated antibodies. C 0, direct Western blotting using anti-Flag antibody. C00
immunoprecipitation with anti-HBx antibody to show HBx expression. c, coCul1 or Skp1 (Fig. 3A) were disrupted in the presence of
HBx. Similarly, the Skp1–Skp2 interaction was also down
regulated by HBx. Like c-Myc, the interaction of p21Waf1
with Skp1 and Skp2 was also negatively regulated (3B). Fur-
ther, a direct correlation between the intracellular levels of
HBx and displacement of Skp1 from both c-Myc- and
p21Waf1-recruited SCFSkp2 complexes (Fig. 3C) substantiated
the regulatory mechanism involving HBx. The observed
interference is unlikely to be due to a direct interaction be-
tween HBx and Skp1 since co-immunoprecipitation studies
with anti-HBx or anti-Skp1 antibodies failed to conﬁrm this
(data not shown).3.4. HBx stabilizes c-Myc by inhibiting ubiquitination
Since ubiquitination ﬂags target proteins to proteosomal
degradation, we monitored the ubiquitination of c-Myc in
the presence of HBx. As shown in Fig. 4A, HBx dramatically
reduced the ubiquitination of c-Myc (compare lanes 2 and 3).g of either control vector or expression vectors of HBx (X0) (A), or X0
). The cell lysates were immunoprecipitated and Western blotted with
, Western blotting using anti-HBx antibody. * in panel D (lane 2), direct
ntrol vector; IgH, immunoglobulin heavy chain.
Fig. 3. Interaction of c-Myc and p21Waf1 with the SCFSkp2 complex in the presence of HBx. (A, B) Huh7 cells were transfected with 2 lg each of
either c-Myc, c-Myc and X0, HA-21 or HA-21 with X0 plasmids and the cell lysates were immunoprecipitated (IP) and Western blotted (WB) with
indicated antibodies. (C) Cells were transfected with 2 lg of control vector (c), c-Myc (upper panel) or HA-p21 (lower panel) and increasing
amounts of X0 (lanes 4–6). In upper panel, the cell lysates were immunoprecipitated with anti-Myc antibody and blotted with anti-Skp1 antibody
(lanes 2–6). In lower panel, the lysates were immunoprecipitated with anti-Skp1 antibody followed by Western blotting with anti-p21 antibody (lanes
1 and 3–6). +c, controls for direct Western blotting. The lysates 3–6 from both panels were also Western blotted to show the quantitative expression
of HBx.
Fig. 4. Ubiquitination and stability of c-Myc in the presence HBx. (A) Vectors expressing individual proteins ubiquitin (Ub), c-Myc and HBx (X0)
were transfected in Huh7 cells either alone: Ub (1 lg) or in combinations with c-Myc (2 lg) or Myc + X0 (2 lg each). Cells were treated with MG132
(50 lM) 2 h prior to harvesting and the cell lysates were immunoprecipitated with anti-Myc antibody followed by Western blotting with anti-Ub
antibody. IgH, immunoglobulin heavy chain. (B) Cells transfected with either c-Myc alone (2 lg) or along with X0 (2 lg each) and pulse labeled with
[35S]-methionine and cysteine mix for indicated time periods. The cell lysates were immunoprecipitated using anti-Myc antibody, resolved by 10%
SDS–PAGE and autoradiographed (top panel). The stability of c-Myc as analyzed by densitometry is shown as bar diagram (middle panel).
Expression of HBx in these samples was also conﬁrmed (lower panel).
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stability of c-Myc in the presence of HBx (Fig. 4B).4. Discussion
Precise and timely regulation of cellular proteins holds the
key for proper maintenance of cellular homeostasis. The tar-
geting of proteins to proteasomes through interaction withUb ligases is central to normal cellular regulatory mechanism.
Oncogenic viruses have acquired diﬀerent strategies to subvert
the proteasomal activity of target cells [24,25]. The multifunc-
tional regulatory X protein of HBV, that is implicated in the
development of HCC, has also been shown to downregulate
the proteasomal functions [11,12]. Here, we show that HBx
can enhance the intracellular stability of c-Myc by blocking
its ubiquitination. We hypothesize that a sustained level of c-
Myc could be important for the development of HCC.
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between HBx and Skp2. The fact that HBx selectively binds to
Skp2 and not to b-TrCP, suggests that the Skp2 substrate pro-
teins may be the natural targets of HBV during viral infection.
Further, our mutational studies suggested that the amino-
terminal F box region of Skp2 was essential for binding to
HBx. Apparently, the carboxy terminal leucine-rich repeat
(LRR) region of Skp2 which is essential for the interaction
of substrate proteins such as c-Myc [19,20], was not required.
Although, DC Skp2 binds to HBx, it fails to interfere with the
HBx-mediated stabilization of c-Myc (data not shown). It is
possible that DC Skp2 may not act as a DN because it lacks
the LRR domain to recognize substrate proteins. Since the se-
quence of events for the assembly of an active SCF complex is
poorly understood, it is possible that binding of substrates to F
box protein could initiate the process. The speciﬁc interaction
between HBx and Skp2, nevertheless, prompted us to check
whether HBx itself was a substrate of Skp2-mediated proteaso-Fig. 5. Possible mechanism of oncogenic cooperativity between HBx and c-
the SCFSkp2 complex. Skp2 binds to c-Myc through the LRR domain and to
(pathway B), the interaction between Skp1 and Skp2 is disrupted because HB
ubiquitination of c-Myc prolonging its half-life. The proliferative actions ofmal degradation. Our results clearly indicated that HBx is not
a substrate of Skp2 because it gets degraded with a half-life of
20 min even in the presence of the DN mutant DF Skp2. Nev-
ertheless, increase in the intracellular levels of HBx by protea-
some inhibitors and accumulation of its polyubiquitinated
forms [11,23] could be due to the involvement of a diﬀerent
E3 Ub ligase.
We also noted that some of the key biochemical interactions
in the Ub-proteasomal pathway, like those between c-Myc and
Skp2, Cul1 or Skp1 and Skp2 and Skp1 were negatively regu-
lated by HBx. Since HBx binds to Skp2 through F box region
it is likely to disrupt Skp1–Skp2 interaction for a common
binding site [3]. Note that interference with Skp1 functions
could induce ampliﬁcation of c-myc gene, chromosomal insta-
bility and neoplastic transformation in the Cul1-N252 trans-
genic mice [26]. Therefore, interference with the Skp1
function by HBx may be conducive for development of HCC
although there is no physical interaction between these two pro-Myc. c-Myc undergoes proteasomal degradation via ubiquitination by
Skp1 through the F box region (pathway A). In the presence of HBx
x binds to Skp2 through the F box. As a result, there is inhibition in the
c-Myc and HBx could act synergistically in cell transformation.
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the enhanced levels of some key transcription factors and their
prolonged intracellular availability may accentuate the pleio-
tropic actions of HBx. Besides HBx and Skp2 may act synergis-
tically in cell transformation since both proteins are known to
cooperate with Ras [27,28]. Besides, it would be interesting to
probe the interaction of HBx with another F box protein
Fbw7 that also regulates c-Myc [21,22]. Further studies will
also be necessary to determine the fate of cdk inhibitors like
p21Waf1 in the presence of HBx since the former is degraded
via both Ub-dependent and independent pathways [29].
Considering the oncogenic potential of c-Myc, it is critical
that its intracellular availability and activity be tightly regu-
lated. We observed that the ubiquitination of c-Myc was dra-
matically lowered in the presence of HBx. Under normal
physiological condition, c-Myc showed a half life of approxi-
mately 15–20 min. The Myc level was sustained for a consider-
able period (>1 h) in the presence of HBx. Further, there was a
marked increase in its intracellular stability of c-Myc due to
HBx. As shown in Fig. 5, the enhanced Myc stability combined
with its sustained eﬀects on proliferation and diﬀerentiation
may lead to genomic instability and tumorigenesis [30]. Fur-
ther, secondary signals generated by HBx such as inhibition
of Myc-mediated apoptosis, deregulation of cell cycle check-
points and increased survival signals such as pAkt could pro-
vide a perfect milieu for cell transformation [18]. Thus, HBV
appears to be a consummate example of a virus that has devised
mechanisms of compelling healthy cells to use their own house-
keeping machinery in a way that make them cancerous.
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